At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
In Brief
A Phase 3 clinical trial evaluating 3-Dimensional Conformal Radiation Therapy, Bevacizumab, and 5 other interventions for Glioblastoma and 2 related conditions. Completed, enrolled 637 participants across 330 sites in 3 countries.
Detailed Summary
This randomized phase III trial studies temozolomide (TMZ) and radiation therapy (RT) to compare how well they work with or without bevacizumab in treating patients with newly diagnosed glioblastoma or gliosarcoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as bevacizumab, may find tumor cells and help kill them. It is not yet known whether temozolomide and radiation therapy are more effective when given together with or without bevacizumab in treating glioblastoma or gliosarcoma.
Study Details
Timeline
Interventions
Undergo 3-dimentional conformal radiation therapy
Given IV
Undergo intensity-modulated radiation therapy
Correlative studies
Given IV
Ancillary studies
Given orally